Core Insights - Iovance's Q4 2025 revenue reached $86.77 million, a quarter-over-quarter increase of approximately 30%, with gross margin improving significantly to 50%, marking a shift from "technical validation" to "large-scale commercialization" in the TIL therapy sector [1][2] - Chinese companies, represented by Junshi Biosciences, are innovating to reduce treatment costs and enhance accessibility for TIL therapies, indicating a competitive edge in the market [1][4] Financial Performance - Iovance's stock price surged by 30.8% to $3.78 on the day of the earnings report, marking the largest single-day increase in two years, with after-hours trading pushing it to $3.877 [2] - The revenue of $86.77 million exceeded analyst expectations, and the gross margin increased from 43% in Q3 to 50%, indicating improved production processes and market acceptance [2][3] Clinical Developments - The FDA granted Lifileucel fast track designation for non-small cell lung cancer, with the registration trial expected to complete patient enrollment in the first half of the year [2] - Iovance reported a 50% objective response rate (ORR) in a pilot trial for refractory soft tissue sarcoma, suggesting the TIL technology platform's potential across multiple solid tumor indications [3] Competitive Landscape - Junshi Biosciences is leading a shift in TIL therapy by developing GC101, which does not require high-intensity chemotherapy or IL-2 injections, addressing significant safety and accessibility issues [4][5] - The clinical data for GC101 shows a 41.7% ORR and a 66.7% disease control rate (DCR) in late-stage non-small cell lung cancer, positioning it as a competitive alternative to traditional therapies [6][8] Market Outlook - The period of 2026-2027 is anticipated to be a critical window for TIL therapies, with Iovance's success raising the probability of success for solid tumor cell therapies [9] - Investment strategies are shifting towards assets with confirmed data, differentiated technology, and clear commercialization paths, benefiting companies like Junshi Biosciences [10]

Corporate Overview February 2026 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. 1 Forward-Looking Statements Certain matters discussed in this presentation are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Without limiting the foregoing, we may, in some cases, use terms such as "predicts," "believes," "potentia ...

Group 1 - Iovance Biotherapeutics Inc. expects to achieve full-year 2025 revenue guidance of $250 to $300 million in the first full calendar year of Amtagvi sales [1][2] - Amtagvi, the treatment regimen for advanced melanoma, is projected to have peak sales potential of up to $1 billion [1] - The company has $307 million in cash and cash equivalents, which will fund operations through the second quarter of 2027 [2] Group 2 - Lifileucel, an in-development treatment for lung cancer, has a commercial opportunity that could be up to 7 times larger than the current melanoma treatment market [2] - Enrollment and data updates for Lifileucel are expected to be completed this year, with a launch anticipated in the second half of 2027 [2] - Iovance Biotherapeutics specializes in developing and commercializing cell therapies as novel cancer immunotherapy products [2]